INS and cancer: Insulin resistance is a central component of the MetSyn and is arguably one of the most important features of metabolic dysfunction in relation to cancer due to the mitogenic effects of insulin on breast cancer cells [15] and the substantial evidence linking hyperinsulinemia and insulin resistance to cancer prognosis [3].